Fig. 7
From: The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells
High levels IL6 plus PTGER2 plus PTGER4 correlate with adverse outcomes in breast cancer patients. a Log2 expression of IL-6 plus PTGER2 plus PTGER4 in basal (n = 357), HER2 (n = 152), luminal A (n = 482), luminal B (n = 289), normal-like (n = 257), and unclassified (n = 344) tumors. b Log2 expression of IL-6 plus PTGER2 plus PTGER4 in ER-negative (n = 395) and ER-positive (n-1225). c Spearman correlation of IL-6 plus PTGER2 plus PTGER4 with the indicated modules (n = 1881). Kaplan-Meier analysis of distant metastasis-free survival in basal tumors (n = 282), overall survival in BRCA tumors (n = 594) of IL-6 plus PTGER2 plus PTGER4 low expressing (d, gray and e, green), or high expressing (d and e, red) breast cancer patients. f Overall summary model of the data presented in the current studies and the proposed mechanism for the MSCs pro- vs. anti-IRISOE TNBC tumors roles